Compare Merck & Co., Inc. (MRK) vs Vivmark Residential Common Shares of Beneficial Interest (VMRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vivmark Residential Common Shares of Beneficial Interest — how do they compare? Merck & Co., Inc. trades at $142.39 (market cap $352.29B), while Vivmark Residential Common Shares of Beneficial Interest trades at $60.01 (market cap $45.88B). The key difference: Merck & Co., Inc. is far larger — about 7.7× Vivmark Residential Common Shares of Beneficial Interest's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays the higher dividend (4.74%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Vivmark Residential Common Shares of Beneficial Interest for 0 Days on average.
| MRK | VMRK | |
|---|---|---|
Market Cap | $352.29B | $45.88B |
Volume | 6,348,796 | 4,028,975 |
Sector | Health | Real Estate |
52-Week High | $156.43 | $70.15 |
52-Week Low | $82.49 | $57.98 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $399.05B | $54.98B |
Dividend Yield | 2.38% | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vivmark Residential Common Shares of Beneficial Interest
Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.
Read more on VMRK →
